MMM

3M Company (MMM) - 2003 Annual Report (10-K) Summary

Business Context and Reporting Period

This filing covers the fiscal year ended December 31, 2003. 3M is a diversified global technology company operating in seven reportable segments: Health Care, Industrial, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, Electro and Communications, and Transportation. The company employs approximately 67,000 people globally. In 2003, 3M executed a two-for-one stock split and continued a strategic realignment initiated in 2002 to focus on market growth.

Key Financial Metrics

Material Changes vs. Prior Period

• Sales Growth: Net sales increased 11.6% to a record $18.2 billion. Growth was driven by 4.7% core volume growth, 1.9% from acquisitions, and 5.2% from favorable foreign currency translation.
• Profitability: Operating income rose 21.9% due to sales growth, cost savings from corporate initiatives (Six Sigma, Global Sourcing), and the completion of the 2001/2002 restructuring program.
• Segment Performance:
  • Display and Graphics: Sales surged 33.0% and operating income 65.8%, driven by optical film sales for flat-panel displays and the Corning Precision Lens acquisition.
  • Safety, Security and Protection: Sales grew 14.4% and operating income 29.1%, boosted by demand for respirator masks related to SARS concerns.
  • Electro and Communications: The only segment with declining sales (-0.7%) due to weakness in the global telecommunications industry.
• Special Items: 2003 results included a pre-tax charge of $93 million ($58 million after-tax) related to an adverse antitrust ruling in the LePage's lawsuit. This contrasts with 2002, which included $202 million in restructuring charges.
• Liquidity: Cash and cash equivalents increased by $1.2 billion to $1.8 billion, while total debt decreased by $440 million.

Guidance, Outlook, and Risks

• 2004 Outlook: Management expects solid growth in sales and income. Corporate initiatives are projected to contribute an additional $400 million to operating income. However, pension expenses are expected to increase by approximately $165 million.
• Key Growth Drivers: Focus on organic core growth, new product introductions (specifically Aldara for new indications), and disciplined acquisitions.
• Legal Contingencies:
  • Asbestos/Respirator Litigation: Pending claims increased to ~88,700. The company increased reserves by $231 million to $289 million. The company maintains significant insurance receivables ($448 million) but notes uncertainty regarding future claim volumes and costs.
  • LePage's Antitrust: The company is appealing the $93 million judgment to the U.S. Supreme Court.
  • Environmental: Ongoing EPA reviews regarding perfluorooctanyl chemistry and remediation costs at various sites.
• Market Risks: Exposure to foreign currency fluctuations (hedging covers ~50% of impact), raw material price volatility, and potential impairment of goodwill in the telecommunications sector if market conditions deteriorate.

Investor Verification Checklist

• LePage's Litigation: Monitor the status of the U.S. Supreme Court petition regarding the $93 million antitrust judgment.
• Asbestos Reserves: Review future filings for changes in the $289 million liability reserve and the collectability of the $448 million insurance receivable.
• Pension Funding: Verify actual 2004 pension contributions against the projected range of $100–$600 million and the impact of the $165 million expense increase.
• Pharmaceutical Approvals: Track FDA approval status for new indications of Aldara (imiquimod) Cream, expected mid-2004.
• Telecom Sector: Assess the stability of the Electro and Communications segment given the continued weakness in the telecom industry and the $300 million goodwill exposure.